During the CheckMate-67T trial, the average administration time for BMS’ Opdivo Qvantig was approximately five minutes. Credit: Dennis Diatel/Shutterstock.

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for subcutaneous use to treat various solid tumours.

This new combination product, which includes nivolumab co-formulated with recombinant human hyaluronidase, is intended for use in most previously approved adult solid tumour indications of Opdivo.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Opdivo Qvantig can be used as monotherapy, monotherapy maintenance following treatment with Opdivo plus Yervoy (ipilimumab) combination regimen, or along with chemotherapy or cabozantinib.

The approval is based on the results from the Phase III CheckMate-67T trial.

This randomised, open-label study compared Opdivo Qvantig to intravenous (IV) Opdivo in adults with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who had received systemic therapy previously.

It demonstrated that the treatment with Opdivo Qvantig had non-inferior co-primary pharmacokinetic exposures and similar efficacy in overall response rate (ORR), maintaining a comparable safety profile to IV Opdivo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Subcutaneous administration of Opdivo Qvantig may provide increased flexibility for treatment locations, benefiting both patients and healthcare providers, the company noted.

It also has the potential to streamline preparation and reduce the time needed for administration.

During the CheckMate-67T trial, the average administration time for Opdivo Qvantig was approximately five minutes compared to the 30-minute IV administration of Opdivo.

Bristol Myers Squibb executive vice-president and chief commercialisation officer Adam Lenkowsky said: “At Bristol Myers Squibb, we are committed to helping patients in all aspects of their healthcare journey.

“Over the last decade, Opdivo has evolved as an immunotherapy option used in many indications across tumour types. With this new option, we look forward to further helping cancer patients with an administration method that gives them faster delivery.”

In October this year, BMS received approval from the US FDA for Opdivo to treat adults with resectable non-small cell lung cancer.